POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

BRAF inhibitors (BRAFi) have shown remarkable clinical efficacy in the treatment of melanoma with BRAF mutation. Nevertheless, most patients end up with the development of BRAFi resistance, which strongly limits the clinical application of these agents. POU4F1 is a stem cell-associated transcription...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Liu, Lin, Yue, Qiao, Ma, Jingjing, Liu, Yu, Zhao, Tao, Guo, Weinan, Zhu, Guannan, Guo, Sen, Wang, Shiyu, Gao, Tianwen, Li, Chunying, Shi, Qiong
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293281/
https://ncbi.nlm.nih.gov/pubmed/32532957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2662-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados